Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome

作者: Charles A Dinarello , Jeffrey A Gelfand , Sheldon M Wolff

DOI: 10.1001/JAMA.1993.03500140081040

关键词:

摘要: The systemic inflammatory response syndrome (SIRS) is an acute illness characterized by generalized activation of the endothelium. most severe form found in patients with shock due to gram-negative sepsis. We examined both animal and limited human data for contribution cytokines this syndrome. Cytokines are endogenously produced proteins small molecular weight multiple biological effects. interleukin 1 (IL-1) tumor necrosis factor (TNF), as well interferon-γ 8, discussed. Laboratory investigations suggest that these play a critical role SIRS promoting biochemical clinical characteristics SIRS. changes induced TNF IL-1 include increased synthesis nitric oxide, prostaglandins, platelet-activating factor, endothelial cell adhesion molecules. Specific blockade using neutralizing antibodies or soluble receptors models reduces mortality severity disease. Similar results have been observed blocking receptor antagonists. Preliminary studies may be useful treating various strategies presented; addition, their mechanism(s) action safety humans conclude based on preliminary trials, block benefit syndrome, although thorough trials not completed. ( JAMA . 1993;269:1829-1835)

参考文章(79)
PL McCarthy, S Abhyankar, S Neben, G Newman, C Sieff, RC Thompson, SJ Burakoff, JL Ferrara, Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease Blood. ,vol. 78, pp. 1915- 1918 ,(1991) , 10.1182/BLOOD.V78.8.1915.1915
P Herve, M Flesch, P Tiberghien, J Wijdenes, E Racadot, P Bordigoni, E Plouvier, JL Stephan, H Bourdeau, E Holler, Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease Blood. ,vol. 79, pp. 3362- 3368 ,(1992) , 10.1182/BLOOD.V79.12.3362.3362
K. Z. Guo, R. C. Thompson, J. del Castillo, S. M. Yin, S. P. Eisenberg, T. R. Ulich, The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. American Journal of Pathology. ,vol. 138, pp. 521- 524 ,(1991)
Charles A. Dinarello, Go Wakabayashi, Jeffrey A. Gelfand, John F. Burke, Robert C. Thompson, A specific receptor antagonist for interleukin 1 prevents Escherichia coli ‐induced shock in rabbits The FASEB Journal. ,vol. 5, pp. 338- 343 ,(1991) , 10.1096/FASEBJ.5.3.1825816
D. T. Nguyen, C. Miller, D. G. Remick, Mark Eskandari, L. E. DeForge, G. Bolgos, Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. Journal of Immunology. ,vol. 148, pp. 2724- 2730 ,(1992)
S L Kunkel, J S Bromberg, K D Chavin, Anti-tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. Journal of Immunology. ,vol. 148, pp. 3412- 3417 ,(1992)
J M Dayer, J W Lowenthal, K Williamson, H R MacDonald, P Seckinger, A urine inhibitor of interleukin 1 activity that blocks ligand binding. Journal of Immunology. ,vol. 139, pp. 1546- 1549 ,(1987)
P J Knudsen, T B Strom, C A Dinarello, Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. Journal of Immunology. ,vol. 139, pp. 4129- 4134 ,(1987)
H. Engelmann, H. Holtmann, C. Brakebusch, Y.S. Avni, I. Sarov, Y. Nophar, E. Hadas, O. Leitner, D. Wallach, Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. Journal of Biological Chemistry. ,vol. 265, pp. 14497- 14504 ,(1990) , 10.1016/S0021-9258(18)77330-4
David Wallach, Dan Aderka, Hartmut Engelmann, Yoram Levo, Gil Kushtai, Yehuda Skornick, Vered Hornik, Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Research. ,vol. 51, pp. 5602- 5607 ,(1991)